Quoin Pharmaceuticals (QNRX) Interest Expenses (2020 - 2026)
Quoin Pharmaceuticals (QNRX) posted Interest Expenses of $5.8 million for Q1 2026, up 625.0% sequentially from $800000.0 in Q4 2025, and up 5700.0% YoY from $100000.0 in Q1 2025.
Quoin Pharmaceuticals (QNRX) Interest Expenses (2020 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Interest Expenses for 7 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Interest Expenses rose 5700.0% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 5700.0% YoY) and the FY2025 annual result came in at $12.0 million, up 41.87% from the prior year.
- Interest Expenses improved to $5.8 million in Q1 2026 per QNRX's latest filing, from $800000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $5.8 million in Q1 2026 and troughed at -$187000.0 in Q4 2022.
- A 5-year average of $564357.1 and a median of $102000.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2026: Interest Expenses sank 413.7% in 2022, then surged 5700.0% in 2026.
- Over 5 years, Interest Expenses stood at -$187000.0 in 2022, then jumped by 155.61% to $104000.0 in 2023, then decreased by 3.85% to $100000.0 in 2024, then jumped by 700.0% to $800000.0 in 2025, then soared by 625.0% to $5.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $5.8 million, $800000.0, and $100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Quoin Pharmaceuticals | 531,643.73 | 531,643.73 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.80 Mn |
| Mar 31, 2026 | 5.80 Mn |
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Sep 30, 2023 | 104,000.00 |
| Sep 30, 2023 | 104,000.00 |
| Jun 30, 2023 | 104,000.00 |
| Jun 30, 2023 | 104,000.00 |